<DOC>
	<DOCNO>NCT00000845</DOCNO>
	<brief_summary>To evaluate HIV synthetic lipopeptide candidate vaccine component , P3C541b , two dose level , administer subcutaneously ( s.c. ) randomize , double-blind , placebo control study .</brief_summary>
	<brief_title>A Phase I Safety Immunogenicity Trial UBI HIV Lipopeptide Vaccine Component P3C541b HIV-1 Seronegative Human Subjects</brief_title>
	<detailed_description>The prospective volunteer screen HLA type Class I MHC haplotype . Only volunteer possess HLA allele A33 , B8 , B27 , B35 Bw62 combination thereof enrol study . Subjects allocate 1 2 study group . Group 1 receive 70 mcg P3C541b placebo Group II receive 350 mcg P3C541b placebo . NOTE : Enrollment Group II wil begin least 5 Group I participant reach day 14 without serious adverse event .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must : Healthy Negative ELISA HIV . One HLA allele : A33 , B8 , B27 , B35 , Bw62 . Negative Hepatitis B surface antigen . Normal urine dipstick . Normal history physical examination . Availability followup plan duration study ( 12 month ) . Viable EBV line prior enrollment . Risk behavior : Required : Lower risk sexual behavior define AVEG . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical psychiatric condition occupational responsibility , preclude subject compliance protocol ( e.g. , recent suicidal ideation present psychosis ) . Active syphilis . NOTE : If serology document false positive due remote ( &gt; 6 month ) treat infection , volunteer eligible . Hepatitis B surface antigenemia . Active tuberculosis . NOTE : Volunteers positive PPD normal chest XRay show evidence TB require INH therapy eligible . Patients follow prior condition exclude : History immunodeficiency , chronic illness , malignancy , autoimmune disease . History cancer , unless surgical excision follow sufficient observation period give reasonable assurance cure . History anaphylaxis history serious adverse reaction vaccine . History serious allergic reaction substance , require hospitalization emergent medical care . History suicide attempt past psychosis . Prior Medication : Excluded : History use immunosuppressive medication . Live attenuate vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclusionary give least 2 week away HIV immunization . Use experimental agent within 30 day prior study . Prior Treatment : Excluded : Receipt blood product immunoglobulin past 6 month . Risk Behavior : Excluded : Subjects identifiable high risk behavior HIV infection determine screen questionnaire design identify risk factor HIV infection . History injection drug use within last 12 month prior enrollment . Higher intermediate risk sexual behavior define AVEG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>